Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1002/mdc3.14336 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Parkinsonian presentation in a child with Anti-NMDAR Encephalitis.
Mov Disord Clin Pract
January 2025
Department of Pediatrics, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
Deterioration of preexisting myoclonus following nifedipine use in parkinsonian syndrome: A case report.
eNeurologicalSci
March 2025
Department of Neurology, Nagoya City University Graduate School of Medical Sciences, Aichi, Japan.
L-type calcium channel antagonists are uncommon causes of myoclonus, and the underlying mechanism remains unclear. Here, we report a case of parkinsonian syndrome with deterioration of preexisting myoclonus after nifedipine use. A 96-year-old woman was administered a single dose of sustained-release nifedipine for chest pain.
View Article and Find Full Text PDFMovement Disorders that Occurred as Late Manifestations of Alzheimer's Disease Controlled by a Low dose of Carbamazepine.
Eur J Case Rep Intern Med
December 2024
Department of Geriatrics and Internal Medicine, Champmaillot Hospital, University Hospital, Dijon, France.
Introduction: According to the World Health Organization, 44 million people worldwide suffer from Alzheimer's disease. Abnormal movements are atypical symptoms of Alzheimer's disease.
Case Description: An 87-year-old woman, followed for Alzheimer's disease, experienced abnormal movements.
Rigidity in Parkinson's Disease: The Objective Effect of Levodopa.
Mov Disord
January 2025
Department of Human Neurosciences, Sapienza University of Rome, Rome, Italy.
Background: Quantitative evidence of levodopa-induced beneficial effects on parkinsonian rigidity in Parkinson's disease (PD) is lacking. Recent research has demonstrated the velocity-dependent nature of objective rigidity in PD and revealed its neural underpinning.
Objective: The present study aimed to examine the effect of levodopa on objective rigidity in PD.
Digital measurement of ocular microtremor in Parkinson's disease: Protocol for a pilot study to assess reliability and clinical validation.
PLoS One
January 2025
Department of Sport, Exercise and Rehabilitation, Northumbria University, Newcastle upon Tyne, United Kingdom.
Ocular microtremor (OMT) is a fixational eye movement that cannot be seen with the naked eye but is always present, even when the eye appears motionless/still. The link between OMT and brain function provides a strong rationale for investigation as there lies potential for its use as a biomarker in populations with neurological impairments. OMT frequency is typically 70-80Hz in healthy adults and research suggests that this will be reduced in those with neurological disease such as Parkinson's Disease (PD).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!